1-8 of 8
Hyatt Balke-Want
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Jan-Michel Heger, Julia Mattlener, Jessica Schneider, Philipp Gödel, Noëlle Sieg, Fabian Ullrich, Richard Lewis, Teodora Bucaciuc-Mracica, Roland F. Schwarz, Daniel Rueß, Maximilian I. Ruge, Manuel Montesinos-Rongen, Martina Deckert, Tobias Blau, Nadine Kutsch, Hyatt Balke-Want, Jonathan Weiss, Kerstin Becker, H. Christian Reinhardt, Michael Hallek, Peter Borchmann, Bastian von Tresckow, Sven Borchmann
Journal: Blood
Blood (2024) 143 (6): 522–534.
https://doi.org/10.1182/blood.2023022020
Published: 2024
Includes: Supplemental data
Journal Articles

Putting the pedal to the metal: axi-cel for LBCL

Clinical Trials & Observations
Hyatt Balke-Want
Journal: Blood
Blood (2023) 141 (19): 2285–2286.
https://doi.org/10.1182/blood.2023020188
Published: 2023
Journal Articles

Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

Jan-Michel Heger, Julia Mattlener, Philipp Gödel, Hyatt Balke-Want, Noëlle Sieg, Nadine Kutsch, Kerstin Becker, Jonathan Weiss, H. Christian Reinhardt, Michael Hallek, Peter Borchmann, Bastian von Tresckow, Sven Borchmann
Journal: Blood
Blood (2022) 140 (Supplement 1): 3537–3538.
https://doi.org/10.1182/blood-2022-162420
Published: 2022
Journal Articles

Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

Jan-Michel Heger, Claus Moritz Graef, Philipp Falderbaum, Philipp Gödel, Hyatt Balke-Want, Florian Simon, Noëlle Sieg, Jan-Hendrik Naendrup, Marie Anne-Catherine Neumann, Sarah Gillessen, Paul J Bröckelmann, Dennis A. Eichenauer, Peter Borchmann, Bastian Von Tresckow
Journal: Blood
Blood (2021) 138 (Supplement 1): 2531.
https://doi.org/10.1182/blood-2021-145283
Published: 2021
Journal Articles

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Peter Borchmann, Anja Jühling, Philipp Gödel, Hyatt Balke-Want, Christoph Schmid, Francis A. Ayuk, Silke Holtkamp, Liane Preussner, Gregor Zadoyan, Linda Hanssens, Andrew Kaiser, Marion Jurk, Iris Bürger, Dina Schneider, Boro Dropulic, Toon Overstijns, Christof Scheid, MD, Udo Holtick, Stefan Miltenyi, Michael Hallek
Journal: Blood
Blood (2020) 136 (Supplement 1): 48.
https://doi.org/10.1182/blood-2020-136067
Published: 2020
Journal Articles

Clonal Evolution of a Mutation in PTPRA As a Potential Cause for Resistance Against Anti-CD19 Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with CTL019 in DLBCL Patients

Hyatt Balke-Want, MD, Philipp Gödel, MD, Nima Abedpour, PhD, Martin Peifer, PhD, Peter Borchmann, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4119.
https://doi.org/10.1182/blood-2018-99-110600
Published: 2018
Journal Articles

Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients

Rakesh Awasthi, PhD, Karen Thudium Mueller, PharmD,MSc, Gregory A. Yanik, MD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Susana Rives, MD PhD, Joseph P. McGuirk, DO, Michael A. Pulsipher, MD, Michael W. Boyer, MD, Ulrich Jaeger, MD, Andre Baruchel, MD, Gary Douglas Myers, MD, Hyatt Balke-Want, MD, Stephen J. Schuster, MD, Heather Stefanski, MD PhD, Michael R. Bishop, MD, Edward R. Waldron, PhD MSc, BSc, Özlem Anak, MD, Abhijit Chakraborty, PhD, Eric Bleickardt, MD, Stephane Wong, PhD MBA, Lida Bubuteishvili Pacaud, MD, Edmund K. Waller, MD, Shannon L. Maude, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 899.
https://doi.org/10.1182/blood-2018-99-116385
Published: 2018
Journal Articles

Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Julia von Tresckow, MD, Jasmin Bahlo, PhD, Sandra Robrecht, Anja Engelke, MD, Petra Langerbeins, MD, Anna-Maria Fink, MD, Hyatt Balke-Want, MD, Othman Al-Sawaf, MD, Till Seiler, MD, Ludwig Fischer von Weikersthal, MD, Holger Hebart, MD, Kirsten Fischer, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, Barbara F. Eichhorst, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 2044.
https://doi.org/10.1182/blood.V128.22.2044.2044
Published: 2016